| 126.28 0.01 (0.01%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 152  |
1-year : | 159.55 |
| Resists | First : | 130.13 |
Second : | 136.6 |
| Pivot price | 130.53  |
|||
| Supports | First : | 119.68 |
Second : | 99.57 |
| MAs | MA(5) : | 126.63 |
MA(20) : | 129.83 |
| MA(100) : | 117.1 |
MA(250) : | 95.05 |
|
| MACD | MACD : | 0.9 |
Signal : | 2 |
| %K %D | K(14,3) : | 20.9 |
D(3) : | 21.5 |
| RSI | RSI(14): 47.8 |
|||
| 52-week | High : | 136.6 | Low : | 59.22 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GKOS ] has closed above bottom band by 18.7%. Bollinger Bands are 17.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 128.75 - 129.24 | 129.24 - 129.81 |
| Low: | 124.62 - 125.15 | 125.15 - 125.76 |
| Close: | 125.3 - 126.15 | 126.15 - 127.12 |
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Fri, 13 Sep 2024
Thornburg Investment Management Inc. Takes Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
Wed, 11 Sep 2024
Glaukos Co. (NYSE:GKOS) Director Sells $392,010.00 in Stock - MarketBeat
Wed, 11 Sep 2024
Kliman Gilbert H, director at Glaukos Corp, trades company stock - Investing.com
Wed, 11 Sep 2024
Glaukos Corporation: Ripe For Some Consolidation (NYSE:GKOS) - Seeking Alpha
Wed, 11 Sep 2024
Glaukos Stocks Rides on Strong Product Demand Amid Competition - Yahoo Finance
Wed, 11 Sep 2024
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 55 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 100 (%) |
| Shares Short | 2,570 (K) |
| Shares Short P.Month | 2,590 (K) |
| EPS | -3.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.13 |
| Profit Margin | -46.5 % |
| Operating Margin | -28.8 % |
| Return on Assets (ttm) | -8 % |
| Return on Equity (ttm) | -27.5 % |
| Qtrly Rev. Growth | 19 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 6.21 |
| EBITDA (p.s.) | -1.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -71 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -39.59 |
| PEG Ratio | -7.6 |
| Price to Book value | 10.41 |
| Price to Sales | 20.3 |
| Price to Cash Flow | -97.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|